Found: 445
Select item for more details and to access through your institution.
Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?".
- Published in:
- Journal of the American Geriatrics Society, 2024, v. 72, n. 9, p. 2874, doi. 10.1111/jgs.19015
- By:
- Publication type:
- Article
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019.
- Published in:
- PLoS Medicine, 2023, v. 20, n. 11, p. 1, doi. 10.1371/journal.pmed.1004309
- By:
- Publication type:
- Article
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.
- Published in:
- PLoS Medicine, 2023, v. 19, n. 3, p. 1, doi. 10.1371/journal.pmed.1004190
- By:
- Publication type:
- Article
Understanding when real world data can be used to replicate a clinical trial: A cross‐sectional study of medications approved in 2011.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1273, doi. 10.1002/pds.5086
- By:
- Publication type:
- Article
Using real‐world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1322, doi. 10.1002/pds.4994
- By:
- Publication type:
- Article
Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2017, v. 26, n. 6, p. 694, doi. 10.1002/pds.4205
- By:
- Publication type:
- Article
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2017, v. 26, n. 6, p. 712, doi. 10.1002/pds.4215
- By:
- Publication type:
- Article
Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2017, v. 26, n. 5, p. 597, doi. 10.1002/pds.4177
- By:
- Publication type:
- Article
Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2016, v. 25, n. 8, p. 944, doi. 10.1002/pds.4009
- By:
- Publication type:
- Article
A cross-national comparison of 17 countries' insulin glargine drug labels.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2015, v. 24, n. 2, p. 159, doi. 10.1002/pds.3704
- By:
- Publication type:
- Article
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 1, p. e225218, doi. 10.1001/jamahealthforum.2022.5218
- By:
- Publication type:
- Article
Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
- Published in:
- JAMA Health Forum, 2023, v. 4, n. 1, p. e225012, doi. 10.1001/jamahealthforum.2022.5012
- By:
- Publication type:
- Article
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
- Published in:
- JAMA Health Forum, 2022, v. 3, n. 8, p. e222685, doi. 10.1001/jamahealthforum.2022.2685
- By:
- Publication type:
- Article
Medicare Spending on Drugs With Accelerated Approval, 2015-2019.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 12, p. 1, doi. 10.1001/jamahealthforum.2021.3937
- By:
- Publication type:
- Article
Estimating Rebates and Other Discounts Received by Medicare Part D.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 6, p. 1, doi. 10.1001/jamahealthforum.2021.0626
- By:
- Publication type:
- Article
Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities.
- Published in:
- American Journal of Public Health, 2022, v. 112, n. 8, p. 1110, doi. 10.2105/ajph.2022.306888
- By:
- Publication type:
- Article
Drug Shortages and the Defense Production Act.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Pain Management and Opioid Regulation: Continuing Public Health Challenges.
- Published in:
- American Journal of Public Health, 2019, v. 109, n. 1, p. 31, doi. 10.2105/AJPH.2018.304881
- By:
- Publication type:
- Article
Eliminating Coverage Discrimination Through the Essential Health Benefit's Anti-Discrimination Provisions.
- Published in:
- American Journal of Public Health, 2017, v. 107, n. 2, p. 253, doi. 10.2105/AJPH.2016.303563
- By:
- Publication type:
- Article
Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review.
- Published in:
- American Journal of Public Health, 2015, v. 105, n. 2, p. e17, doi. 10.2105/AJPH.2014.302240
- By:
- Publication type:
- Article
Regulating Physician Expert Witness Testimony.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Role of Professional Organizations in Regulating Physician Expert Witness Testimony.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
The Role of Litigation in Defining Drug Risks.
- Published in:
- JAMA: Journal of the American Medical Association, 2007, v. 297, n. 3, p. 308, doi. 10.1001/jama.297.3.308
- By:
- Publication type:
- Article
Clinical Performance Measures and Medical Malpractice.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Will Physician-Level Measures of Clinical Performance Be Used in Medical Malpractice Litigation?
- Published in:
- JAMA: Journal of the American Medical Association, 2006, v. 295, n. 15, p. 1831, doi. 10.1001/jama.295.15.1831
- By:
- Publication type:
- Article
Biomedical Patents and the Public's Health.
- Published in:
- JAMA: Journal of the American Medical Association, 2006, v. 295, n. 4, p. 434, doi. 10.1001/jama.295.4.434
- By:
- Publication type:
- Article
Biotechnology Products and University-Based Science—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2005, v. 293, n. 23, p. 2861, doi. 10.1001/jama.293.23.2863-a
- By:
- Publication type:
- Article
University-Based Science and Biotechnology Products: Defining the Boundaries of Intellectual Property.
- Published in:
- JAMA: Journal of the American Medical Association, 2005, v. 293, n. 7, p. 850, doi. 10.1001/jama.293.7.850
- By:
- Publication type:
- Article
Medicaid Spending on Antiretrovirals From 2007 Through 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 5, p. 833, doi. 10.1093/cid/ciac833
- By:
- Publication type:
- Article
Premarket Development Times for Innovative Vaccines––To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
- Published in:
- Clinical Infectious Diseases, 2022, v. 74, n. 2, p. 347, doi. 10.1093/cid/ciab389
- By:
- Publication type:
- Article
Reply to Boucher et al.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 9, p. e422, doi. 10.1093/cid/ciaa095
- By:
- Publication type:
- Article
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 7, p. 1671, doi. 10.1093/cid/ciz1039
- By:
- Publication type:
- Article
Reputation and Authority: The FDA and the Fight over U.S. Prescription Drug Importation.
- Published in:
- Vanderbilt Law Review, 2020, v. 73, n. 5, p. 1331
- By:
- Publication type:
- Article
The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 7, p. e2419873, doi. 10.1001/jamanetworkopen.2024.19873
- By:
- Publication type:
- Article
Quantifying Research and Development Expenditures in the Drug Industry.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 1, p. e2353094, doi. 10.1001/jamanetworkopen.2023.53094
- By:
- Publication type:
- Article
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 11, p. e2343285, doi. 10.1001/jamanetworkopen.2023.43285
- By:
- Publication type:
- Article
What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?
- Published in:
- AMA Journal of Ethics, 2022, v. 24, n. 11, p. 1083, doi. 10.1001/amajethics.2022.1083
- By:
- Publication type:
- Article
How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?
- Published in:
- AMA Journal of Ethics, 2021, v. 23, n. 9, p. 673, doi. 10.1001/amajethics.2021.673
- By:
- Publication type:
- Article
Why Are Biosimilars Not Living up to Their Promise in the US?
- Published in:
- AMA Journal of Ethics, 2019, v. 21, n. 8, p. 668, doi. 10.1001/amajethics.2019.668
- By:
- Publication type:
- Article
Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
- Published in:
- AMA Journal of Ethics, 2016, v. 18, n. 7, p. 727, doi. 10.1001/journalofethics.2016.18.7.pfor1-1607
- By:
- Publication type:
- Article
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997.
- Published in:
- Journal of Pharmaceutical Policy & Practice, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s40545-020-00282-8
- By:
- Publication type:
- Article
Trends in Medicare Part D Inhaler Spending: 2012-2018.
- Published in:
- 2021
- By:
- Publication type:
- letter
Trends in Medicare Part D Inhaler Spending: 2012–2018.
- Published in:
- Annals of the American Thoracic Society, 2021, v. 18, n. 3, p. 445
- By:
- Publication type:
- Article
Using malpractice claims to identify risk factors for neurological impairment among infants following non-reassuring fetal heart rate patterns during labour.
- Published in:
- Journal of Evaluation in Clinical Practice, 2010, v. 16, n. 3, p. 476, doi. 10.1111/j.1365-2753.2009.01148.x
- By:
- Publication type:
- Article
Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence.
- Published in:
- Drugs, 2018, v. 78, n. 4, p. 523, doi. 10.1007/s40265-018-0890-x
- By:
- Publication type:
- Article
The evidence landscape in precision medicine.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 540, p. 1, doi. 10.1126/scitranslmed.aaw7745
- By:
- Publication type:
- Article
Translational research and the U.S. federal elections.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Electronic medication packaging devices and medication adherence: a systematic review.
- Published in:
- 2014
- By:
- Publication type:
- journal article